A Non Profit Organization
EPEMED Luxembourg asbl is a non-profit organization under the Luxembourg law, registered in Luxembourg at 59, rue du dix Octobre, L-7243 Luxembourg Bereldange.
The organisation is directed by an Executive Director comprised of a dynamic and diverse group of European leaders in the personalised medicine field, who have great expertise in the application and development of diagnostic tools to deliver improved patient care.
Iain Miller is Founder of Healthcare Strategies Group, which he set up in March, 2013. This London-based group focuses on providing strategic advisory services for the diagnostic, device, genomics, and life science tools sectors. In this capacity, he is an active contributor to several international policy initiatives, including The European PErsonalised MEDicine association (EPEMED), where he has served as a board member since its inception in 2009. Iain is also a member of the Technology Appraisal Committee of NICE, which reviews submissions for new drugs and companion tests for use in the UK NHS.
Iain sat on the Steering Committee of the Epemed / Charite Berlin European market access study, due for publication in late 2014., and led in 2011 the writing of a white paper addressing the market access challenges in the EU for high medical value diagnostic tests. He also published a paper in the September 2014 issue of Current Pharmacogenomics and Personalized Medicine titled “Best Practices and Emerging Trends for Market Access to Personalised Medicine in the US and EU: Learnings for Global Developed and Emerging Markets”, and served on the Steering Committee of the UK Academy of Medical Sciences Stratified Medicine market access report, which published in 2013.
He is a healthcare strategy and commercial development executive with over 20 years of diverse healthcare technology experience gained in a variety of settings and geographies. Prior to Healthcare Strategies Group, he was with GE Healthcare, where he served as Global Head, Personalized Healthcare Strategy & Partnerships. Previously, at bioMerieux, Iain was responsible for oncology strategy and also led strategy and business development for the Personalized Medicine Business Unit.
His experience base also includes founding of two medical technology startups, leadership roles in two venture-backed genomics companies, and a technology transfer executive role at Massachusetts General Hospital in Boston. Iain holds a Ph.D. in Biomedical Engineering from the University of Strathclyde, an MBA from Edinburgh Business School and a bachelors degree in Physics from the University of Glasgow.